CLOV logo

Clover Health Investments, Corp. Stock Price

NasdaqGS:CLOV Community·US$2.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 105 Fair Values set on narratives written by author

CLOV Share Price Performance

US$4.68
1.66 (54.97%)
US$4.15
Fair Value
US$4.68
1.66 (54.97%)
12.8% overvalued intrinsic discount
US$4.15
Fair Value
Price US$4.68
AnalystConsensusTarget US$4.15
AnalystLowTarget US$3.50
AnalystHighTarget US$4.75

CLOV Community Narratives

·
Fair Value US$4.15 12.8% overvalued intrinsic discount

Margin Pressures and Healthcare Reforms Will Influence Future Medicare Advantage Dynamics

1users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
·
Fair Value US$3.5 33.7% overvalued intrinsic discount

Rising Costs And Regulation Will Erode Medicare Advantage Profitability

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$4.75 1.5% undervalued intrinsic discount

Digital Healthcare And Medicare Advantage Will Unlock Long-term Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

CLOV logo

CLOV: Rising 2026 Confidence And AI Care Gains Will Frame Q2 Test

Fair Value: US$4.75 1.5% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLOV logo

CLOV: Elevated P/E Expectations Will Pressure Returns Despite Recent Operational Tailwinds

Fair Value: US$4.15 12.8% overvalued intrinsic discount
44 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CLOV logo

CLOV: Elevated P E Expectations Will Likely Pressure Future Share Returns

Fair Value: US$3.5 33.7% overvalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
3 Rewards

Clover Health Investments, Corp. Key Details

US$2.2b

Revenue

US$1.8b

Cost of Revenue

US$405.8m

Gross Profit

US$462.7m

Other Expenses

-US$56.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 05, 2026
-0.11
18.36%
-2.58%
0%
View Full Analysis

About CLOV

Founded
2014
Employees
724
CEO
Andrew Toy
WebsiteView website
www.cloverhealth.com

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

Recent CLOV News & Updates

Narrative Update Jul 13

CLOV: Rising 2026 Confidence And AI Care Gains Will Frame Q2 Test

Clover Health Investments' analyst price target has shifted from $3.20 to $4.75, as analysts point to updated fair value estimates and assumptions around discount rate, revenue growth, profit margin and future P/E to support the change. Analyst Commentary Recent Street research on Clover Health Investments shows a cluster of higher price targets, suggesting that bullish analysts are reworking their models to reflect updated views on fair value, execution and the company’s longer term growth potential.

Recent updates

No updates